Combination chemotherapy for advanced breast cancer.Two regimens containing adriamycin

Publisher Website
Google Scholar
Abstract
Forty-eight women with advanced metastatic carcinoma of the breast were treated with one of two combination chemotherapy regimens: 1) adriamycin and cyclophosphamide or 2) adriamycin, cyclophosphamide, methotrexate and 5-fluorouracil. The response rate in the two-drug treatment group was 50% and in the four-drug treatment group, 55%. The median duration of response was ten months in both treatment groups. Dramatic responses were seen in patients with visceral metastases. Patients who responded to chemotherapy had a significantly longer survival than nonresponders (p<0.01). The long interval between adriamycin doses (six weeks) in the four drug regimen did not adversely effect the response rate—an important finding in view of the dose-related cardiac toxicity of this agent.